2.4 Study treatment
In this study, patients were treated with HDM SLIT-tablet (ACARIZAX®;
12-SQ-HDM sublingual lyophilizate immunotherapy ALK-Abelló A/S,
Hørsholm, Denmark). HDM SLIT-tablet is approved for the treatment of HDM
induced AR by the Dutch authorities since July 2016 and reimbursed as of
October 2017. HDM SLIT-tablet is a lyophilisate containing standardized
allergen extract from two house-dust-mite species, D.
pteronyssinus and D. farinae. The first dose was
self-administered under medical supervision, and subjects were monitored
for 30 minutes after first intake. Subsequent doses were
self-administered at home. The tablet was to be placed under the tongue
and allowed to remain there until dissolved. Subjects were advised not
to swallow during the first minute after administration, food and
beverage was not allowed for 5 minutes thereafter. The study duration
was one year.